Sonoma Historical Income Statement
| SNOA Stock | USD 2.79 0.13 4.45% |
Historical analysis of Sonoma Pharmaceuticals income statement accounts such as Gross Profit of 5.1 M, Other Operating Expenses of 22.2 M, Research Development of 1.7 M or Cost Of Revenue of 6.5 M can show how well Sonoma Pharmaceuticals performed in making a profits. Evaluating Sonoma Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Sonoma Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Sonoma Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Sonoma Pharmaceuticals is a good buy for the upcoming year.
Sonoma |
About Sonoma Income Statement Analysis
Sonoma Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Sonoma Pharmaceuticals shareholders. The income statement also shows Sonoma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Sonoma Pharmaceuticals Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Sonoma Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Sonoma Pharmaceuticals minus its cost of goods sold. It is profit before Sonoma Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Sonoma Pharmaceuticals. It is also known as Sonoma Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Sonoma Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Sonoma Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.At present, Sonoma Pharmaceuticals' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 13.3 M, whereas Interest Expense is forecasted to decline to about 13.7 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 4.0M | 4.5M | 4.7M | 5.1M | Total Revenue | 12.6M | 13.3M | 12.7M | 11.3M |
Sonoma Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Sonoma Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sonoma Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 602K | 227K | 409K | 298K | 176K | 296.7K | |
| Interest Expense | 33K | 16K | 12K | 10K | 14.4K | 13.7K | |
| Selling General Administrative | 13.6M | 9.4M | 9.7M | 8.7M | 7.4M | 13.3M | |
| Total Revenue | 18.9M | 18.6M | 12.6M | 13.3M | 12.7M | 11.3M | |
| Gross Profit | 8.3M | 6.6M | 4.0M | 4.5M | 4.7M | 5.1M | |
| Other Operating Expenses | 25.6M | 22.1M | 18.5M | 17.8M | 17.4M | 22.2M | |
| Operating Income | (6.7M) | (3.4M) | (5.9M) | (4.6M) | (4.7M) | (4.9M) | |
| Ebit | (6.7M) | (3.4M) | (6.1M) | (4.7M) | (4.7M) | (4.9M) | |
| Research Development | 1.3M | 555K | 125K | 207K | 1.9M | 1.7M | |
| Ebitda | (6.1M) | (3.2M) | (5.7M) | (4.4M) | (4.5M) | (4.8M) | |
| Cost Of Revenue | 10.6M | 12.1M | 8.6M | 8.8M | 8.0M | 6.5M | |
| Total Operating Expenses | 15.0M | 10.0M | 9.9M | 9.0M | 9.4M | 15.8M | |
| Income Before Tax | (2.8M) | (3.9M) | (5.4M) | (5.2M) | (5.0M) | (5.3M) | |
| Total Other Income Expense Net | 3.8M | (453K) | 469K | (614K) | (330K) | (313.5K) | |
| Net Income | (2.9M) | (4.6M) | (5.1M) | (5.2M) | (4.8M) | (5.1M) | |
| Income Tax Expense | 121K | 713K | (332K) | (33K) | (196K) | (186.2K) | |
| Net Income From Continuing Ops | (2.9M) | (4.6M) | (5.1M) | (5.2M) | (4.8M) | (5.1M) | |
| Non Operating Income Net Other | 258K | 190K | 3.6M | 153K | 137.7K | 130.8K | |
| Net Income Applicable To Common Shares | (2.9M) | (4.0M) | (5.1M) | (5.2M) | (4.6M) | (4.9M) | |
| Interest Income | 258K | 190K | 50K | 16K | 18.4K | 17.5K | |
| Tax Provision | 121K | 713K | (332K) | (33K) | (196K) | (205.8K) | |
| Net Interest Income | 34K | 4K | (10K) | 16K | 14.4K | 13.7K | |
| Reconciled Depreciation | 312K | 227K | 186K | 125K | 176K | 225.0K | |
| Selling And Marketing Expenses | 35K | 41K | 86K | 156K | 179.4K | 115.7K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.